Thermo Fisher Scientific (NYSE:TMO)‘s stock had its “strong-buy” rating reissued by equities researchers at Needham & Company LLC in a report issued on Thursday, MarketBeat reports. They presently have a $315.00 price target on the medical research company’s stock, up from their prior price target of $313.00. Needham & Company LLC’s target price would indicate a potential upside of 15.89% from the company’s current price.

Other equities analysts have also issued research reports about the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, May 6th. BTIG Research raised their price objective on Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. Argus raised their price objective on Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 30th. Finally, Bank of America reaffirmed a “buy” rating and set a $300.00 price objective (up previously from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $295.92.

NYSE:TMO opened at $271.80 on Thursday. The firm has a market capitalization of $108.71 billion, a P/E ratio of 24.44, a price-to-earnings-growth ratio of 1.74 and a beta of 1.11. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.16 and a current ratio of 1.69. Thermo Fisher Scientific has a 12 month low of $202.83 and a 12 month high of $282.98.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.74 by $0.07. The firm had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.04 billion. Thermo Fisher Scientific had a return on equity of 17.06% and a net margin of 12.89%. Thermo Fisher Scientific’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.50 earnings per share. Analysts predict that Thermo Fisher Scientific will post 12.2 EPS for the current fiscal year.

In other news, CEO Marc N. Casper sold 50,713 shares of the stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $273.21, for a total transaction of $13,855,298.73. Following the completion of the sale, the chief executive officer now owns 302,193 shares in the company, valued at $82,562,149.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Gregory J. Herrema sold 19,808 shares of the stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $253.29, for a total transaction of $5,017,168.32. Following the sale, the senior vice president now owns 25,688 shares of the company’s stock, valued at approximately $6,506,513.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 76,320 shares of company stock worth $20,405,269. Corporate insiders own 0.45% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. CX Institutional acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $36,000. Freestone Capital Holdings LLC boosted its stake in shares of Thermo Fisher Scientific by 46.1% during the fourth quarter. Freestone Capital Holdings LLC now owns 10,081 shares of the medical research company’s stock worth $2,256,000 after buying an additional 3,180 shares during the period. Putnam FL Investment Management Co. boosted its stake in shares of Thermo Fisher Scientific by 2.9% during the fourth quarter. Putnam FL Investment Management Co. now owns 29,001 shares of the medical research company’s stock worth $6,490,000 after buying an additional 810 shares during the period. Buckingham Asset Management LLC boosted its stake in shares of Thermo Fisher Scientific by 6.9% during the first quarter. Buckingham Asset Management LLC now owns 2,106 shares of the medical research company’s stock worth $576,000 after buying an additional 136 shares during the period. Finally, Steinberg Global Asset Management boosted its stake in shares of Thermo Fisher Scientific by 21.1% during the first quarter. Steinberg Global Asset Management now owns 5,747 shares of the medical research company’s stock worth $1,187,000 after buying an additional 1,000 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: Technical Analysis of Stocks, How Can It Help

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.